About Eikon
Eikon is a company based in Hayward (United States) founded in 2019 by Robert Tjian, Luke Lavis, and Eric Betzig.. Eikon has raised $1.16 billion across 4 funding rounds from investors including ARE, T. Rowe Price and StepStone Group. Eikon offers products and services including Therapeutic Platform, Pipeline, and Eikon Systems. Eikon operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, Nimbus Therapeutics and BioNTech, among others.
- Headquarter Hayward, United States
- Founders Robert Tjian, Luke Lavis, Eric Betzig
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eikon Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.16 B (USD)
in 4 rounds
-
Latest Funding Round
$350.7 M (USD), Series D
Feb 14, 2025
-
Investors
ARE
& 21 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Eikon
Eikon is a publicly listed company on the NASDAQ with ticker symbol EIKN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Eikon
Eikon offers a comprehensive portfolio of products and services, including Therapeutic Platform, Pipeline, and Eikon Systems. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for developing and managing therapeutic products
System for advancing therapeutic drug pipelines
Systems for reporting and handling product safety concerns
Unlock access to complete
Unlock access to complete
Software Development Team
41 people
Leadership Team
31 people
Senior Team
14 people
Human Resources and Administration
7 people
Board Team
6 people
Finance and Accounting
6 people
Data Analysis and Operations Team
5 people
Staff Team
5 people
Unlock access to complete
Funding Insights of Eikon
Eikon has successfully raised a total of $1.16B across 4 strategic funding rounds. The most recent funding activity was a Series D round of $350.7 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $350.7M
-
First Round
First Round
(05 May 2021)
- Investors Count 22
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Series D - Eikon | Valuation |
investors |
|
| Jun, 2023 | Amount | Series C - Eikon | Valuation |
investors |
|
| Jan, 2022 | Amount | Series B - Eikon | Valuation | T. Rowe Price , CPP Investments |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eikon
Eikon has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, T. Rowe Price and StepStone Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Founded Year | Domain | Location | |
|
AME Cloud Ventures is focused on investing in data-driven technology companies.
|
Founded Year | Domain | Location | |
|
Early-stage investments in US life science startups are focused on.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eikon
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Eikon
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eikon Comparisons
Competitors of Eikon
Eikon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, Nimbus Therapeutics and BioNTech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eikon
Frequently Asked Questions about Eikon
When was Eikon founded?
Eikon was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Eikon located?
Eikon is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Who is the current CEO of Eikon?
Roger M Perlmutter is the current CEO of Eikon.
Is Eikon a funded company?
Eikon is a funded company, having raised a total of $1.16B across 4 funding rounds to date. The company's 1st funding round was a Series B of $517.8M, raised on May 05, 2021.
What does Eikon do?
Eikon was founded in 2019 and is headquartered in Hayward, United States. The company operates in the biotechnology sector, focusing on drug discovery through a therapeutic platform. Protein dynamics are analyzed by researchers using live-cell super-resolution microscopy integrated with computing and engineering technologies. This approach supports the identification and evaluation of potential drug targets.
Who are the top competitors of Eikon?
Eikon's top competitors include ADMA Biologics, Nimbus Therapeutics and BioNTech.
What products or services does Eikon offer?
Eikon offers Therapeutic Platform, Pipeline, and Eikon Systems.
Is Eikon publicly traded?
Yes, Eikon is publicly traded on NASDAQ under the ticker symbol EIKN.
Who are Eikon's investors?
Eikon has 22 investors. Key investors include ARE, T. Rowe Price, StepStone Group, Schroders, and CPP Investments.
What is Eikon's ticker symbol?
The ticker symbol of Eikon is EIKN on NASDAQ.